A sign hangs near the section for children's medicine at a Walgreens in New York City on Dec.19, 2022. (Photo by Fatih Aktas/Anadolu Agency via Getty Images)
Walgreens has ended limits it had imposed recently for online purchases of children’s over-the-counter fever reducing products.
The drugstore chain said improved supplies allowed it to lift its restriction of six products. The company had placed no limit on in-store purchases.
Last month both Walgreens and CVS Health restricted purchases of some over-the-counter children’s medicines citing supply issues. CVS Health put a two-product limit on all children’s pain relief products bought through its pharmacies or online.
A CVS Health spokeswoman said Tuesday that limits on some children's medicines remain in place. She did not offer a time frame for when it might end.
An unusually fast start to the annual U.S. flu season, plus a spike in other respiratory illnesses, created a surge in demand for fever relievers and other products people can buy without a prescription.
Shortages of medicines like Children’s Tylenol developed, varying around the country and sometimes even within communities.
Experts who track medicine shortages said in December that the problem could persist through the winter cold-and-flu season. But they noted that it should not last as long as other recent shortages of baby formula or prescription drugs.
Skift airline reporter Meghna Maharishi breaks down how the government shutdown is hitting air traffic control—and what it means for travelers and flight safety
Aya Kantorovich, Co-CEO of August Digital, breaks down Bitcoin’s surge, crypto ETFs, institutional investment trends, and the future of safer crypto access.
Most members of the Federal Reserve’s interest-rate setting committee supported further reductions to its key interest rate this year, minutes from last month’s meeting showed.
Sinead O’Sullivan breaks down Taylor Swift’s genius marketing for The Life of a Showgirl, which just set the record for most albums sold in a single week.
Markets are emerging from a turbulent Q3. Horizon’s Mike Dickson shares insights on interest rates, small caps, and where investors should look in Q4 and beyond
